Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours

Next Previous
X
Search
Trial Profile

A Phase I/II Open-Label, Three-Part, Dose-Finding and Separate Cohort Expansion Trial to Assess the Safety, Tolerability and Preliminary Efficacy of Repeated Doses of CLEVER-1 Antibody FP-1305, in Subjects With Advanced Solid Tumours

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 15 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bexmarilimab (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Gastric cancer; Liver cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Skin cancer; Solid tumours; Thyroid cancer; Uveal melanoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms MATINS
  • Sponsors Faron Pharmaceuticals

    • Most Recent Events

    • 13 Jan 2024 This trial has been Completed in Finland, According to European Clinical Trials Database record.
    • 07 Dec 2023 According to a Faron Pharmaceuticals media release, Petri Bono, MD, PhD., Chief Medical Officer is a Principal Investigator of the MATINS study.
    • 07 Dec 2023 Results a Faron Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top